Citadel Group — Major Shareholding Notification 2023

May 15, 2023

National Storage Mechanism | Additional information

RNS Number : 4218Z

Citadel Group

15 May 2023

Ap27

FORM 8.3

IRISH TAKEOVER PANEL

OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER

RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1.             KEY INFORMATION

(a)   Full name of discloser	Citadel Group
(b)   Owner or controller of interests and short positions disclosed, if different from 1(a) The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.	N/A
(c)   Name of offeror/offeree in relation to whose relevant securities this form relates Use a separate form for each offeror/offeree	HORIZON THERAPEUTICS PLC
(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree (Note 1)	N/A
(e)   Date position held/dealing undertaken For an opening position disclosure, state the latest practicable date prior to the disclosure	12 May 2023
(f)    In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state "N/A"	N/A

2.             INTERESTS AND SHORT POSITIONS

If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.

Ap28

Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

(Note 2)

Class of relevant security (Note 3)	Common Stock ISIN IE00BQPVQZ61
	Interests		Short positions
Number	%	Number	%
(1)   Relevant securities owned and/or controlled	4,166,360	1.82	0	0.00
(2)   Cash-settled derivatives	0	0.00	0	0.00
(3)   Stock-settled derivatives (including options) and agreements to purchase/ sell	425,000	0.18	375,000	0.16
Total	4,591,360	2.00	375,000	0.16

All interests and all short positions should be disclosed.

Details of options including rights to subscribe for new securities and any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8.

3.             DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE (Note 4)

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)           Purchases and sales

Class of relevant security	Purchase/sale	Number of securities	Price per unit (Note 5)
Common	Buy Transaction	106	108.2777 USD
Common	Buy Transaction	786	108.6063 USD
Common	Buy Transaction	605	108.8127 USD
Common	Buy Transaction	100	109.1700 USD
Common	Buy Transaction	200	109.3300 USD
Common	Buy Transaction	15,888	109.3360 USD
Common	Buy Transaction	2,200	109.3366 USD
Common	Buy Transaction	3,301	109.9114 USD
Common	Buy Transaction	1,248	110.7831 USD
Common	Buy Transaction	5,924	110.7881 USD
Common	Buy Transaction	2,139	110.8014 USD
Common	Buy Transaction	9,352	111.0000 USD
Common	Buy Transaction	5,526	111.1317 USD
Common	Buy Transaction	2,765	111.1344 USD
Common	Buy Transaction	13,813	111.1346 USD
Common	Buy Transaction	419	111.1366 USD
Common	Buy Transaction	300	111.1600 USD
Common	DVP Transaction	677	111.0000 USD
Common	RVP Transaction	677	111.0000 USD
Common	Sell Transaction	911	108.2825 USD
Common	Sell Transaction	3,159	108.6230 USD
Common	Sell Transaction	600	108.7283 USD
Common	Sell Transaction	2,136	108.9138 USD
Common	Sell Transaction	9,956	108.9169 USD
Common	Sell Transaction	3,341	108.9225 USD
Common	Sell Transaction	388	108.9703 USD
Common	Sell Transaction	5,817	109.0166 USD
Common	Sell Transaction	2,316	109.0195 USD
Common	Sell Transaction	1,152	109.0293 USD
Common	Sell Transaction	5,219	109.0379 USD
Common	Sell Transaction	600	109.0433 USD
Common	Sell Transaction	200	109.0525 USD
Common	Sell Transaction	1,494	109.0623 USD
Common	Sell Transaction	600	109.0758 USD
Common	Sell Transaction	1,608	109.0808 USD
Common	Sell Transaction	300	109.0850 USD
Common	Sell Transaction	940	109.0921 USD
Common	Sell Transaction	4,681	109.5084 USD
Common	Sell Transaction	4,500	109.7200 USD
Common	Sell Transaction	100	109.7650 USD
Common	Sell Transaction	1,360	110.0451 USD
Common	Sell Transaction	602	110.1059 USD
Common	Sell Transaction	100	110.1500 USD
Common	Sell Transaction	1,712	110.1710 USD
Common	Sell Transaction	201	110.4547 USD
Common	Sell Transaction	161	111.0000 USD
Common	Sell Transaction	69,641	111.1587 USD

Ap29

(b)           Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/ closing a long/ short position, increasing/ reducing a long/ short position	Number of reference securities (Note 6)	Price per unit (Note 5)

(c)           Stock-settled derivative transactions (including options)

(i)            Writing, selling, purchasing or varying

Class of relevant security	Product description e.g. call option	Writing, purchasing, selling, varying etc.	Number of securities to which option relates (Note 6)	Exercise price per unit	Type e.g. American, European etc.	Expiry date	Option money paid/ received per unit
Common	Put Option	Buy Transaction	150	97.0000 USD	American	2023-May-26	2.4000 USD
Common	Put Option	Sell Transaction	150	107.0000 USD	American	2023-May-26	4.9000 USD

(ii)           Exercise

Class of relevant security	Product description e.g. call option	Exercising/ exercised against	Number of securities	Exercise price per unit (Note 5)

(d)           Other dealings (including transactions in respect of new securities) (Note 3)

Class of relevant security	Nature of dealing e.g. subscription, conversion, exercise	Details	Price per unit (if applicable) (Note 5)

Ap30

4.             OTHER INFORMATION

(a)           Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer. Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"
None

(b)           Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
None

(c)           Attachments

Is a Supplemental Form 8 attached?	YES

Date of disclosure	15 May 2023
Contact name	Paula Sharp
Telephone number	020 7645 9700

Public disclosures under Rule 8.3 of the Rules must be made to a Regulatory Information Service.

Ap32

SUPPLEMENTAL FORM 8

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1, RULE 8.3, RULE 38.5(b) AND

RULE 38.6 OF THE IRISH TAKEOVER PANEL ACT, 1997,

TAKEOVER RULES, 2022

DETAILS OF OPEN STOCK-SETTLED DERIVATIVE (INCLUDING

OPTION) POSITIONS, AGREEMENTS TO PURCHASE OR SELL AND

RIGHTS TO SUBSCRIBE FOR NEW SECURITIES

1.             KEY INFORMATION

Full name of person making disclosure:	Citadel Group
Name of offeror/offeree in relation to whose relevant securities the disclosure relates:	HORIZON THERAPEUTICS PLC

2.             STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS)

Class of relevant security	Product description e.g. call option	Written or purchased	Number of securities to which option or derivative relates	Exercise price per unit	Type e.g. American, European etc.	Expiry date
Common	Put Option	Sold	50,000	100 USD	American	18/08/2023
Common	Call Option	Purchased	50,000	115 USD	American	18/08/2023
Common	Put Option	Sold	30,000	100 USD	American	19/05/2023
Common	Put Option	Sold	280,000	90 USD	American	21/07/2023
Common	Put Option	Sold	15,000	107 USD	American	26/05/2023
Common	Put Option	Purchased	- 50,000	80 USD	American	18/08/2023
Common	Put Option	Purchased	- 30,000	85 USD	American	19/05/2023
Common	Put Option	Purchased	- 280,000	105 USD	American	21/07/2023
Common	Put Option	Purchased	- 15,000	97 USD	American	26/05/2023

3.             AGREEMENTS TO PURCHASE OR SELL

Full details should be given so that the nature of the interest or position can be fully understood:

Ap33

4.             RIGHTS TO SUBSCRIBE FOR NEW SECURITIES (INCLUDING DIRECTORS' AND OTHER EMPLOYEE OPTIONS)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

It is not necessary to provide details on a Supplemental Form with regard to cash-settled derivatives.

The currency of all prices and other monetary amounts should be stated.

For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.

References in these notes to "the Rules" are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ITPGPUMGAUPWUBA